Loading
A phase 3 trial of aumolertinib in lung cancer, run by Shanghai Cancer Hospital, China, now recruiting.
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT05800223 by Shanghai Cancer Hospital, China, with a registry enrolment figure of 300 participants, started 2023-01-01 and due to reach its primary completion in 2027-12. Interventions recorded: Almonertinib; SBRT. Conditions listed: Non-small Cell Lung Cancer Metastatic. Primary outcome: iPFS. Lung eligibility wording from the registry: "histologically confirmed NSCLC (by AJCC 8th edition lung cancer staging criteria)". Sites: China. No results are recorded here; the registry entry is the source.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.